In 2021, a new drug to treat bone marrow cancer showed enough promise in early trials that the Food and Drug Administration ...

Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration ...

We found more than two-thirds of rheumatologists received industry payments. Rheumatologists often prescribe expensive new ...

With legislative efforts to combat drug shortages picking up and amid a record high numbe | A report from U.S. Pharmacopeia ...

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable ...

Drug companies are paying Australian doctors millions of dollars a year to fly to overseas conferences and meetings, give ...

The nonbinding vote is a potential setback for psychedelic advocates hoping to move the banned drugs into the mainstream.

AdvertisementAstraZeneca completed the acquisition of Canada-based Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing radioconjugates (RCs). The acquisition is part of ...

CSPC Pharmaceutical beat market forecasts with double-digit growth in first-quarter revenues and profits, driven by rising sales of drugs to treat strokes and dementia  The company has dozens of ...

Almost a dozen drug providers report losing sensitive data, all as a result of the Cencora February 2024 breach.

Post updated on 5/25 to add three more pharmaceutical firms also impacted by the Cencora security breach. Some of the largest ...